Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01177319 · ClinicalTrials.gov registry record · Phase 2

Glutathione (GSH) In The Treatment of Parkinson's Disease

A Phase 2 study, sponsored by University of South Florida.

Completed
Registry status
Phase 2
Development phase
20
Enrollment target

NCT01177319 is a Phase 2 study that has completed, run by University of South Florida. The registered enrollment target is 20 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01177319, a Phase 2 study, has completed, sponsored by University of South Florida.

COMPLETED
Registry status
Phase 2
Development phase
20 participants
Enrollment target

Study Summary

This is an investigator initiated pilot study to examine the effects of GSH in PD. The goal of this study is to acquire some basic data regarding side effects and efficacy of this compound to determine if this is a possible treatment option that could be recommended to interested PD patients.

Interventions

  • DRUG Glutathione

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2003-09
Est. Completion 2007-03
Phase Phase 2

Sponsor

University of South Florida

252 total trials

What the Registry Record Tells You About NCT01177319

The ClinicalTrials.gov registry entry for NCT01177319 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of South Florida, which has 252 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Glutathione is the first listed.

NCT01177319 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01177319 about?

NCT01177319 is a clinical study titled "Glutathione (GSH) In The Treatment of Parkinson's Disease". This is an investigator initiated pilot study to examine the effects of GSH in PD. The goal of this study is to acquire some basic data regarding side effects and efficacy of this compound to determine if this is a possible treatment option that could be recommended to interested PD patients.

What is the current status of trial NCT01177319?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2003-09. Estimated completion is 2007-03.

What interventions are being tested in trial NCT01177319?

The interventions under investigation include: Glutathione (DRUG).

Who is sponsoring clinical trial NCT01177319?

This trial is sponsored by University of South Florida, which has 252 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.